-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Tc8oMJcxtKBZi81M/CvjYoJekFSHtGzaqo0OmFZhF5CcvaWOKUk/RLohMZnGCuSj oNtPVvw0aIK1d08kRsyXrw== 0000898432-08-000129.txt : 20080214 0000898432-08-000129.hdr.sgml : 20080214 20080214163217 ACCESSION NUMBER: 0000898432-08-000129 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20080214 DATE AS OF CHANGE: 20080214 GROUP MEMBERS: BIOTECHNOLOGY VALUE FUND II, L.P. GROUP MEMBERS: BVF INC. GROUP MEMBERS: BVF INVESTMENTS, L.L.C. GROUP MEMBERS: BVF PARTNERS L.P. GROUP MEMBERS: INVESTMENT 10, L.L.C. SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: SGX PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001125603 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 061523147 STATE OF INCORPORATION: DE FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-81448 FILM NUMBER: 08617166 BUSINESS ADDRESS: STREET 1: 10505 ROSELLE STREET CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-558-4850 MAIL ADDRESS: STREET 1: 10505 ROSELLE STREET CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: STRUCTURAL GENOMIX INC DATE OF NAME CHANGE: 20001002 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BIOTECHNOLOGY VALUE FUND L P CENTRAL INDEX KEY: 0000918923 STANDARD INDUSTRIAL CLASSIFICATION: INVESTMENT ADVICE [6282] IRS NUMBER: 363924731 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: 900 N. MICHIGAN AVENUE, SUITE 1100 CITY: CHICAGO STATE: IL ZIP: 60611 BUSINESS PHONE: 3125066500 MAIL ADDRESS: STREET 1: 900 N. MICHIGAN AVENUE, SUITE 1100 CITY: CHICAGO STATE: IL ZIP: 60611 SC 13G/A 1 sgxpharmsc13ga.htm



SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549


SCHEDULE 13G

(Rule 13d-102)


INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

TO RULES 13d-1(b) (c) AND (d) AND AMENDMENTS THERETO FILED

PURSUANT TO 13d-2(b)


(Amendment No. 2)*




SGX Pharmaceuticals, Inc.

(Name of Issuer)


 

Common Stock

(Title of Class of Securities)


 

78423C108

(CUSIP Number)


 

December 31, 2007

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:



 

 

£   Rule 13d-1(b)

S   Rule 13d-1(c)

£   Rule 13d-1(d)



*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.


The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).





 

 

 

 

 

CUSIP No. 78423C108

 

13G

 

Page 2 of 10 Pages

 

 

 

 

 

1

 

 NAME OF REPORTING PERSON:

 Biotechnology Value Fund, L.P.

 I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY):

 

 

 

2

 

 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

 

(a)S 

 

 

 

 

(b)£ 

 

 

 

 

 

 

3

 

 SEC USE ONLY

 

 


 


 


 


 


 

 

4

 

 CITIZENSHIP OR PLACE OF ORGANIZATION


 


 


 Delaware


 


 

 

 

 

5

 

 SOLE VOTING POWER

NUMBER OF

 

 

 

 0

SHARES

 

 

BENEFICIALLY

 

6

 

 SHARED VOTING POWER

OWNED

 

 

 

 389,400

BY

 

 

EACH

 

7

 

 SOLE DISPOSITIVE POWER

REPORTING

 

 

 

 0

PERSON

 

 

WITH:

 

8

 

 SHARED DISPOSITIVE POWER

 

 

 

 

 389,400

 

9

 

 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

 


 


 


 389,400


 


 

 

10

 

 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

 

£


 


 


 


 


 

 

11

 

 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

 


 


 


1.9%


 


 

 

12

 

 TYPE OF REPORTING PERSON*

 

 

 


 

 PN

 

 







 

 

 

 

 

CUSIP No. 78423C108

 

13G

 

Page 3 of 10 Pages

 

 

 

 

 

1

 

 NAME OF REPORTING PERSON:

 Biotechnology Value Fund II, L.P.

 I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY):

 

 

 

2

 

 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

 

(a)S 

 

 

 

 

(b)£ 

 

3

 

 SEC USE ONLY

 

 

 

 

 

 

 

 

4

 

 CITIZENSHIP OR PLACE OF ORGANIZATION

 

 


 


 


 Delaware


 


 

 

 

 

5

 

 SOLE VOTING POWER

NUMBER OF

 

 

 

 0

SHARES

 

 

BENEFICIALLY

 

6

 

 SHARED VOTING POWER

OWNED

 

 

 

 263,700

BY

 

 

EACH

 

7

 

 SOLE DISPOSITIVE POWER

REPORTING

 

 

 

 0

PERSON

 

 

WITH:

 

8

 

 SHARED DISPOSITIVE POWER

 

 

 

 

 263,700

 

9

 

 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

 


 


 


 263,700


 


 

 

10

 

 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

 

£


 


 


 


 


 


11

 

 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

 

 

 

 

 

 

 

 

 1.3%

 

 

 

12

 

 TYPE OF REPORTING PERSON*

 

 

 

 

 

 

 

 

 

PN

 

 










 

 

 

 

 

CUSIP No. 78423C108

 

13G

 

Page 4 of 10 Pages

 

 

 

 

 

 

1

 

 NAME OF REPORTING PERSON:

 BVF Investments, L.L.C.

 I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY):

 

 

 

2

 

 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

 

(a)S 

 

 

 

 

(b)£ 

 

 

 

 

 

 

3

 

 SEC USE ONLY

 

 


 


 


 


 


 

 

4

 

 CITIZENSHIP OR PLACE OF ORGANIZATION

 

 


 


 


 Delaware


 


 

 

 

 

5

 

 SOLE VOTING POWER

NUMBER OF

 

 

 

 0

SHARES

 

 

BENEFICIALLY

 

6

 

 SHARED VOTING POWER

OWNED

 

 

 

 1,002,200

BY

 

 

EACH

 

7

 

 SOLE DISPOSITIVE POWER

REPORTING

 

 

 

 0

PERSON

 

 

WITH:

 

8

 

 SHARED DISPOSITIVE POWER

 

 

 

 

 1,002,200

 

9

 

 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

 

 

 

 

 

 

 

 

1,002,200

 

 

 

10

 

 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

 

£

 

 

 

 

 

 

11

 

 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

 

 

 

4.9%

 

 

 

12

 

 TYPE OF REPORTING PERSON*

 

 

 

 

 

 

 

 

 

 OO

 

 









 

 

 

 

 

CUSIP No. 78423C108

 

13G

 

Page 5 of 10 Pages

 

 

 

 

 

 

1

 

 NAME OF REPORTING PERSON:

 Investment 10, L.L.C.

 I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY):

 

 

 

2

 

 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

 

(a)S 

 

 

 

 

(b)£ 

 

 

 

 

 

 

3

 

 SEC USE ONLY

 

 


 


 


 


 


 

 

4

 

 CITIZENSHIP OR PLACE OF ORGANIZATION

 

 


 


 


 Illinois


 


 

 

 

 

5

 

 SOLE VOTING POWER

NUMBER OF

 

 

 

 0

SHARES

 

 

BENEFICIALLY

 

6

 

 SHARED VOTING POWER

OWNED

 

 

 

 114,600

BY

 

 

EACH

 

7

 

 SOLE DISPOSITIVE POWER

REPORTING

 

 

 

 0

PERSON

 

 

WITH:

 

8

 

 SHARED DISPOSITIVE POWER

 

 

 

 

 114,600

 

9

 

 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

 


 


 


 114,600


 


 

 

10

 

 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

 

£


 


 


 


 


 

 

11

 

 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

 


 


 


 0.6%


 


 

 

12

 

 TYPE OF REPORTING PERSON*

 

 

 

 

OO

 

 











 

 

 

 

 

CUSIP No. 78423C108

 

13G

 

Page 6 of 10 Pages

 

 

 

 

 

1

 

 NAME OF REPORTING PERSON:

 BVF Partners L.P.

 I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY):

 

 

 

2

 

 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

 

(a)S 

 

 

 

 

(b)£ 

 

 

 

 

 

 

3

 

 SEC USE ONLY

 

 


 


 


 


 


 

 

4

 

 CITIZENSHIP OR PLACE OF ORGANIZATION

 

 


 


 


 Delaware


 


 

 

 

 

5

 

 SOLE VOTING POWER

NUMBER OF

 

 

 

 0

SHARES

 

 

BENEFICIALLY

 

6

 

 SHARED VOTING POWER

OWNED

 

 

 

 1,769,900

BY

 

 

EACH

 

7

 

 SOLE DISPOSITIVE POWER

REPORTING

 

 

 

 0

PERSON

 

 

WITH:

 

8

 

 SHARED DISPOSITIVE POWER

 

 

 

 

 1,769,900

 

9

 

 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

 


 


 


 1,769,900


 


 

 

10

 

 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

 

£


 


 


 


 


 

 

11

 

 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

 


 


 


 8.6%


 


 

 

12

 

 TYPE OF REPORTING PERSON*

 

 

 

 

 

 

 

 

 

PN

 

 





 

 

 

 

 

CUSIP No. 78423C108

 

13G

 

Page 7 of 10 Pages

 

 

 

 

 

1

 

 NAME OF REPORTING PERSON:

 BVF Inc.

 S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY):

 

 

 

2

 

 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

 

(a)S 

 

 

 

 

(b)£ 

 

 

 

 

 

 

3

 

 SEC USE ONLY

 

 


 


 


 


 


 

 

4

 

 CITIZENSHIP OR PLACE OF ORGANIZATION

 

 


 


 


 Delaware


 


 

 

 

 

5

 

 SOLE VOTING POWER

NUMBER OF

 

 

 

 0

SHARES

 

 

BENEFICIALLY

 

6

 

 SHARED VOTING POWER

OWNED

 

 

 

 1,769,900

BY

 

 

EACH

 

7

 

 SOLE DISPOSITIVE POWER

REPORTING

 

 

 

 0

PERSON

 

 

WITH:

 

8

 

 SHARED DISPOSITIVE POWER

 

 

 

 

 1,769,900

 

9

 

 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

 


 


 


1,769,900


 


 

 

10

 

 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

 

£


 


 


 


 


 

 

11

 

 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

 


 


 


 8.6%


 


 

 

12

 

 TYPE OF REPORTING PERSON*

 

 

 

 

 

 

 

 

 

 IA, CO

 

 






 

 

 

 

 

CUSIP No. 78423C108

 

13G

 

Page 8 of 10 Pages

 

 

 

 

 


ITEM 1(a).      NAME OF ISSUER:


                         SGX Pharmaceuticals, Inc.(“SGX”)


ITEM 1(b).      ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES:


10505 Roselle Street

San Diego, CA 92121


ITEM 2(a).      NAME OF PERSON FILING:


                         This Amendment No. 2 to Schedule 13G is being filed on behalf of the following persons (the “Reporting Persons”):


 

(i)

 

 Biotechnology Value Fund, L.P. (“BVF”)

 

(ii)

 

 Biotechnology Value Fund II, L.P. (“BVF2”)

 

(iii)

 

 BVF Investments, L.L.C. (“Investments”)

 

(iv)

 

 Investment 10, L.L.C. (“ILL10”)

 

(v)

 

 BVF Partners L.P. (“Partners”)

 

(vi)

 

 BVF Inc. (“BVF Inc.”)


ITEM 2(b).      ADDRESS OF PRINCIPAL BUSINESS OFFICE:


                         The principal business office of the Reporting Persons comprising the group filing this Amendment No. 2 to Schedule 13G is located at 900 North Michigan Avenue, Suite 1100, Chicago, Illinois, 60611.


ITEM 2(c).      CITIZENSHIP:


 

 

 BVF:

 a Delaware limited partnership

 

 

 BVF2:

 a Delaware limited partnership

 

 

 Investments:

 a Delaware limited liability company

 

 

 ILL10:

 an Illinois limited liability company

 

 

 Partners:

 a Delaware limited partnership

 

 

 BVF Inc.:

 a Delaware corporation


ITEM 2(d).      TITLE OF CLASS OF SECURITIES:


                         This Amendment No. 2 to Schedule 13G is being filed with respect to the common stock, par value $0.001 per share (“Common Stock”), of SGX.  The Reporting Persons’ percentage ownership of Common Stock is based on 20,480,282 shares of Common Stock being outstanding.


                 

    As of December 31, 2007 BVF beneficially owned 389,400 shares of Common Stock, BVF2 beneficially owned 263,700 shares of Common Stock, Investments beneficially owned 1,002,200 shares of Common Stock and ILL10 beneficially owned 114,600 shares of Common Stock.  Beneficial ownership by Partners and BVF Inc. includes 1,769,900 shares of  Common Stock.




ITEM 2(e).      CUSIP Number:


                       78423C108


 

 

 

 

 

CUSIP No. 78423C108

 

13G

 

Page 9 of 10 Pages

 

 

 

 

 


ITEM 3.        IF THIS STATEMENT IS FILED PURSUANT TO RULE 13d-1(b), or 13d-2(b) or (c) CHECK WHETHER THE PERSON FILING IS:    One of the following


                        Not applicable as this Amendment No. 2 to Schedule 13G is filed pursuant to Rule 13d-1(c).


ITEM 4.        OWNERSHIP:


                        The information in items 1 and 5 through 11 on the cover pages (pp. 2 - 7) on this Amendment No. 2 to Schedule 13G is hereby incorporated by reference.


ITEM 5.        OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:


                        If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities check the following. 


ITEM 6.        OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:


                        Pursuant to the operating agreement of Investments, Partners is authorized, among other things, to invest the funds of Ziff Asset Management, L.P., the majority member of Investments, in shares of the Common Stock beneficially owned by Investments and to vote and exercise dispositive power over those shares of the Common Stock. Partners and BVF Inc. share voting and dispositive power over shares of the Common Stock beneficially owned by BVF, BVF2, Investments and those owned by ILL10, on whose behalf Partners acts as an investment manager and, accordingly, Partners and BVF Inc. have beneficial ownership of all of the shares of the Common Stock owned by such parties.


ITEM 7.        IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY:


                        Not applicable.


ITEM 8.        IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF A GROUP:


                        Not applicable.


ITEM 9.        NOTICE OF DISSOLUTION OF GROUP:


                        Not applicable.







 

 

 

 

 

CUSIP No. 78423C108

 

13G

 

Page 10 of 10 Pages

 

 

 

 

 


ITEM 10.        CERTIFICATION


                        By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


                        After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.


Dated:


 


February 14, 2008



 


 


BIOTECHNOLOGY VALUE FUND, L.P.


 


 


By:


 


BVF Partners L.P., its general partner


 


 


 


 


By:


 


BVF Inc., its general partner


 


 


 


 


 


 


By:


 


 /s/ Mark N. Lampert

 

 

 

 

 

 

 

 

 Mark N. Lampert

 President


 


 


BIOTECHNOLOGY VALUE FUND II, L.P.


 


 


By:


 


BVF Partners L.P., its general partner


 


 


 


 


By:


 


BVF Inc., its general partner


 


 


 


 


 


 


By:


 


 /s/ Mark N. Lampert

 

 

 

 

 

 

 

 

 Mark N. Lampert

 President


 


 


BVF INVESTMENTS, L.L.C.


 


 


By:


 


BVF Partners L.P., its manager


 


 


 


 


By:


 


BVF Inc., its general partner


 


 


 


 


 


 


By:


 


 /s/ Mark N. Lampert

 

 

 

 

 

 

 

 

 Mark N. Lampert

 President



 


 


INVESTMENT 10, L.L.C.


 


 


By:


 


BVF Partners L.P., its attorney-in-fact


 


 


 


 


By:


 


BVF Inc., its general partner


 


 


 


 


 


 


By:


 


 /s/ Mark N. Lampert

 

 

 

 

 

 

 

 

 Mark N. Lampert

 President


 


 


BVF PARTNERS L.P.


 


 


By:


 


BVF Inc., its general partner


 


 


 


 


 


 


By:


 


 /s/ Mark N. Lampert

 

 

 

 

 

 

 

 

 Mark N. Lampert

 President


 


 



BVF INC.


 


 


 


 


 


 


By:


 


 /s/ Mark N. Lampert

 

 

 

 

 

 

 

 

 Mark N. Lampert

 President





 -----END PRIVACY-ENHANCED MESSAGE-----